Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO) filed a Current Report on Form 8-K on November 13, 2025. The filing announces the reporting of financial results for the quarter ended September 30, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the quarter ended September 30, 2025.
Material Changes
The filing text does not contain specific data regarding material changes in financial performance compared to prior periods. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These disclosures are contained within the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2025 revenue and net loss figures.
- Verify cash position and burn rate details not included in this 8-K summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the company provided updated full-year 2025 financial guidance.